Avanafil is a PDE5 inhibitor approved for erectile dysfunction by the FDA on April 27, 2012[2] and by EMA on June 21, 2013.

[6] Avanafil acts by inhibiting a specific phosphodiesterase type 5 enzyme found in various body tissues, primarily in the corpus cavernosum penis.

It is absorbed quickly, reaching a maximum serum concentration in about thirty to forty-five minutes.

[8] The most common adverse effects include headache, flushing, nasopharyngitis, nasal congestion, and back pain.

[11] Avanafil's mechanism of action takes places once nitric oxide is released, in association with sexual stimulation.